Bicycle Therapeutics (NASDAQ:BCYC) Sets New 12-Month Low – Should You Sell?

Bicycle Therapeutics plc (NASDAQ:BCYC)’s share price reached a new 52-week low during mid-day trading on Monday . The company traded as low as $8.25 and last traded at $8.64, with a volume of 418 shares trading hands. The stock had previously closed at $8.97.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on BCYC. Stephens reaffirmed an “equal weight” rating and set a $15.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, January 22nd. HC Wainwright reiterated a “buy” rating and issued a $33.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, February 26th. JMP Securities cut their price objective on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a research report on Wednesday, December 18th. Needham & Company LLC restated a “buy” rating and issued a $30.00 price objective on shares of Bicycle Therapeutics in a research note on Tuesday, March 11th. Finally, B. Riley reduced their price target on Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Bicycle Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $29.14.

Bicycle Therapeutics Trading Down 6.1 %

The business has a 50-day moving average price of $11.32 and a 200 day moving average price of $17.52. The stock has a market capitalization of $582.89 million, a P/E ratio of -2.57 and a beta of 1.12.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.75) EPS for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.10. The business had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $5.47 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The business’s revenue was down 30.2% on a year-over-year basis. During the same period last year, the company posted ($1.16) EPS. On average, sell-side analysts predict that Bicycle Therapeutics plc will post -3.06 earnings per share for the current fiscal year.

Insider Transactions at Bicycle Therapeutics

In related news, CAO Travis Alvin Thompson sold 2,686 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $15.00, for a total value of $40,290.00. Following the completion of the transaction, the chief accounting officer now owns 32,146 shares of the company’s stock, valued at $482,190. The trade was a 7.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Kevin Lee sold 9,038 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total value of $127,345.42. Following the sale, the chief executive officer now directly owns 495,026 shares in the company, valued at $6,974,916.34. This trade represents a 1.79 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 27,677 shares of company stock worth $392,413. 8.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Bicycle Therapeutics

Hedge funds have recently made changes to their positions in the stock. Barclays PLC grew its position in shares of Bicycle Therapeutics by 878.3% in the 4th quarter. Barclays PLC now owns 2,612 shares of the company’s stock worth $37,000 after buying an additional 2,345 shares during the last quarter. Avior Wealth Management LLC acquired a new stake in Bicycle Therapeutics in the fourth quarter valued at approximately $57,000. JPMorgan Chase & Co. grew its holdings in Bicycle Therapeutics by 26.8% in the third quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock worth $191,000 after purchasing an additional 1,782 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Bicycle Therapeutics by 30.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,329 shares of the company’s stock worth $131,000 after purchasing an additional 2,191 shares in the last quarter. Finally, Erste Asset Management GmbH purchased a new stake in shares of Bicycle Therapeutics during the 3rd quarter valued at $325,000. 86.15% of the stock is currently owned by hedge funds and other institutional investors.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.